# Discussion Template: Positioning Against Shinya et al. (2025)

## Comparative Analysis: Your GKS Study vs. Shinya et al.

---

## How Your Study Exceeds the Shinya Paper

### 1. Time-to-Event vs. Classification

| Aspect | Shinya et al. | Your Study |
|--------|---------------|------------|
| **Method** | Binary classification (need for intervention) | Survival analysis (time-to-remission) |
| **Information lost** | Time to failure not captured | Full temporal information retained |
| **Clinical relevance** | Static prediction | Dynamic risk over time |

**Positioning:**
> "While Shinya et al. applied classification models to predict the need for additional intervention, we employed time-to-event analysis to characterize the dynamic probability of endocrine remission, recurrence, and treatment-related toxicity over time."

---

### 2. Treatment Strategy Comparison

| Aspect | Shinya et al. | Your Study |
|--------|---------------|------------|
| **Exposure** | Surgery only | Surgery + GKS |
| **Treatment comparison** | Not analyzed | Early vs delayed GKS, targeted vs whole-sella, medication hold |
| **Causal inference** | Not performed | Overlap weighting applied |

**Positioning:**
> "In contrast to Shinya et al., who focused on surgical outcomes, we evaluated the comparative effectiveness of different Gamma Knife radiosurgery strategies, addressing a critical gap in the literature regarding optimal treatment sequencing and planning."

---

### 3. Multicenter Validation

| Aspect | Shinya et al. | Your Study |
|--------|---------------|------------|
| **Design** | Single-center (Mayo) | Multicenter international |
| **Validation** | Internal only (train/test split) | Internal-external cross-validation by center |
| **Generalizability** | Limited | Demonstrated across centers |

**Positioning:**
> "Unlike the single-center cohort in Shinya et al., our international multicenter design with internal-external cross-validation provides stronger evidence for generalizability across diverse practice settings."

---

### 4. Endpoint Complexity

| Aspect | Shinya et al. | Your Study |
|--------|---------------|------------|
| **Primary endpoint** | Intervention-free rate | Endocrine remission (biochemical) |
| **Secondary endpoints** | Not detailed | Recurrence, progression, hypopituitarism, salvage |
| **Multi-state** | Not applied | Disease trajectory modeled |

**Positioning:**
> "We expanded upon the binary outcome used by Shinya et al. by incorporating multiple clinically relevant endpoints and applying multi-state modeling to characterize the dynamic disease trajectory."

---

## Suggested Discussion Paragraph

### Comparison with Prior ML Studies

Several recent studies have applied machine learning to predict outcomes in acromegaly. Shinya et al. developed a supervised learning model achieving 81% accuracy in predicting need for additional intervention after transsphenoidal surgery, identifying tumor size, extent of resection, and Knosp grade as key predictors. While this represents an important contribution, important differences exist between their cohort and ours.

First, we employed time-to-event analysis rather than binary classification, preserving temporal information about when remission, recurrence, and toxicity occur. Second, our study specifically evaluated Gamma Knife radiosurgery as the primary intervention, whereas Shinya et al. focused on surgical outcomes. Third, our multicenter design with internal-external cross-validation provides stronger evidence for generalizability. Finally, we applied causal inference methods (overlap weighting) to address confounding in treatment strategy comparisons.

Collectively, these differences position our study as complementary to prior work while addressing several methodological limitations.

---

## Key Points for Your Discussion

### What to Emphasize

1. **Multicenter > Single-center**
2. **Time-to-event > Classification**
3. **Treatment strategy analysis** (they didn't do this)
4. **Causal inference** (they didn't do this)
5. **Internal-external validation** (stronger than internal only)

### What to Acknowledge

- Their sample size was similar (N~100)
- Both identify similar predictors (tumor size, Knosp grade)
- Both found ML ≈ regression

### What to Avoid

- Don't dismiss their paper entirely
- Acknowledge their contribution to the field
- Position as "building upon" not "replacing"

---

## Template Language

### To cite their work:

> "Shinya et al. (2025) demonstrated that tumor characteristics and surgical outcomes are primary determinants of treatment success in acromegaly."

### To differentiate:

> "In contrast to their single-center surgical cohort, our international multicenter study specifically evaluated Gamma Knife radiosurgery outcomes and applied time-to-event analysis..."

### To show advancement:

> "While Shinya et al. focused on binary classification of treatment need, we employed survival analysis with multi-state modeling to characterize the dynamic disease trajectory..."

---

## Summary Table

| Your Study Advantage | Shinya et al. | Implication |
|---------------------|---------------|-------------|
| Multicenter | Single-center | Better generalizability |
| Time-to-event | Classification | More clinical utility |
| GKS focus | Surgery focus | Addresses different clinical question |
| Causal inference | Not performed | Stronger treatment comparisons |
| IECV | Internal only | More robust validation |

---

*Document created: 2026-03-21*
*For use in Discussion section positioning*
